6/13/2024  6:47:17 PM Chg. +3.22 Volume Bid6:48:18 PM Ask6:48:18 PM Market Capitalization Dividend Y. P/E Ratio
233.73USD +1.39% 19,831
Turnover: 4.61 mill.
233.61Bid Size: 100 236.01Ask Size: 306 33.99 bill.USD - 29.11

Business description

Through cutting-edge science and medicine, Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological, autoimmune and rare diseases. Founded in 1978, Biogen is one of the world’s oldest independent biotechnology companies and patients worldwide benefit from its leading multiple sclerosis and innovative hemophilia therapies.
 

Management board & Supervisory board

CEO
Christopher A. Viehbacher
Management board
Michael McDonnell, Dr. Ginger Gregory, Rachid Izzar, Susan H. Alexander, Nicole Murphy, Priya Singhal
Supervisory board
Caroline Dorsa, Eric K. Rowinsky, Jesus B. Mantas, Maria C. Freire, Stephen A. Sherwin, William A. Hawkins, Susan Langer, Christopher A. Viehbacher
 

Company data

Name: Biogen Inc.
Address: 225 Binney Street,Cambridge, Massachusetts 02142, USA
Phone: +1 781-464-2000
Fax: +1-617-679-2617
E-mail: -
Internet: www.biogen.com
Industry: Biotechnology
Sector: Biotechnology
Sub sector: Biotechnology
End of financial year: 12/31
Free Float: 72.20%
IPO date: -

Investor relations

Name: Karen Jewell
IR phone: 781-464-2442
IR Fax: -
IR e-mail: IR@biogenidec.com

Company calendar

CW 25 | 6/20/2024 General Shareholder Meeting